Adjuvant external beam radiation and brachytherapy for vaginal resection margin positive cervical cancer
- Author:
Donghyun KIM
1
;
Yongkan KI
;
Wontaek KIM
;
Dahl PARK
;
Joohye LEE
;
Jayoung LEE
;
Hosang JEON
;
Jiho NAM
Author Information
- Publication Type:Original Article
- Keywords: Uterine cervical cancer; Brachytherapy; Positive surgical margin; Vaginal recurrence
- MeSH: Brachytherapy; Disease-Free Survival; Drug Therapy; Follow-Up Studies; Humans; Hysterectomy; Medical Records; Neoplasm Metastasis; Pelvis; Recurrence; Retrospective Studies; Survival Rate; Uterine Cervical Neoplasms
- From:Radiation Oncology Journal 2018;36(2):147-152
- CountryRepublic of Korea
- Language:English
- Abstract: PURPOSE: To evaluate the treatment outcomes of adjuvant external beam radiation therapy (EBRT) and vaginal brachytherapy (VB) following radical hysterectomy in cervical cancer patients with involved vaginal resection margin (VRM). MATERIALS AND METHODS: We retrospectively reviewed the medical records of 21 patients treated with postoperative EBRT and VB for positive VRM FIGO stage IB–IIA cervical cancer between 2003 and 2015. Concurrent platinum-based chemotherapy was administered to all patients. RESULTS: The median whole pelvis EBRT dose was 50.4 Gy (range, 45 to 50.4 Gy). In the VB, the median dose per fraction, number of fractions, and total dose delivered were: 4 Gy (range, 3.0 to 4.0 Gy), 4 fractions (range, 3 to 5 fractions), and 16 Gy (range, 12 to 20 Gy), respectively. At a median follow-up of 46 months (range, 9 to 122 months), local recurrence was observed in 2 patients, and distant metastasis was present in 7 patients. All patients with local recurrence subsequently developed distant metastases. The 5-year local control, disease-free survival, and overall survival rates were 89.1%, 65.9%, and 62.9%, respectively. Of the 21 patients, 7 patients (33.3%) reported grade 2 acute toxicity; however, there were no grade 3 or higher acute adverse events. Grade 1–2 late toxicities were observed in 8 patients. Late grade 3 urinary toxicity was reported in 1 patient. CONCLUSIONS: Adjuvant EBRT and VB showed excellent local control and low toxicity in cervical cancer patients with positive VRM. Although limited by its retrospective nature, the findings from our study provide evidence supporting the use of additional VB in pathologically involved VRM.
